Not satisfied with being the world's biggest health-care products company, Johnson & Johnson will expand its already dominant presence in China later this year when it introduces plates and screws manufactured in the country at its Suzhou facility.
Jubilant will use some of the cash to improve its generic drug manufacturing plants in India while also tapping the bank's emerging market healthcare expertise.
Michael Orsinger, chairman of Johnson & Johnson's DePuy Synthes orthopedics unit, said May 22 that customers are demanding a "one stop shop" approach toward implants, predicting that it will drive continued consolidation in the industry.
FDA Commissioner Margaret Hamburg, during a visit to India this year, urged the country to get its regulatory house in order and make sure all of its companies are meeting the highest standards. India, without any reference to Hamburg's plea, says it is doing just that, making a large investment to vastly expand its inspection team.
The GAVI Alliance has already saved about 6 million lives through its funding of low-cost immunization for developing countries. And now, it's looking to save 6 million more through 2020.
The country is in the midst of a full-blown corruption investigation aimed largely at Big Pharma, and now it has picked another target: Swiss drugmaker Roche.
GlaxoSmithKline has been a partner of the GAVI Alliance for years, offering some of its vaccines at low cost to help support immunization efforts for children in emerging countries. But now, it's going one step further with a 5-year price freeze on three of its vaccines for countries that graduate from GAVI funding.
In the face of FDA actions against some of India's biggest drugmakers and a barrage of criticism of its regulators, the Indian government and industry have already responded with a PR campaign, and now India says it will spend more than $500 million to double its inspection staff and upgrade capabilities.
Wipro has won a $400 million contract to manage Takeda's infrastructure. Takeda inked the deal to consolidate its operations, with Wipro becoming its primary provider of IT infrastructure management services.
Any pharma company looking for growth in Egypt has a new target to consider: Amoun Pharmaceutical, one of that country's largest drugmakers. Amoun has hired Jeffries Group to explore a potential sale, Bloomberg reports.